This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Neurology  • Cerebrovascular Disease  • Stroke  • Hematology/ Hematologic Malignancies  • Hematology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Tracy Hampton, PhD

JAMA. 2005;293:415.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A trial designed to see whether children with sickle cell anemia at high risk for stroke could safely stop receiving periodic red blood cell transfusions after a minimum of 30 months was halted last month by the National Heart, Lung, and Blood Institute, in Bethesda, Md. Early results from the Stroke Prevention Trial (STOP) 2 trial indicated that stopping transfusions cannot be recommended (http://www.nhlbi.nih.gov).

New findings indicate that stopping red blood cell transfusions in children with sickle cell anemia increases their stroke risk. (Photo credit: www.sciencesource.com)

The importance of transfusions for sickle cell anemia was established in 1997 following the STOP 1 trial, which indicated that administering blood transfusions every 3 to 4 weeks to such children reduces their rate of first-time stroke by 90%. STOP 2, initiated in 2000, was expected to recruit 100 patients aged 2 to 18 years over a 6-year . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?